Orthofix Announces International Launch of TrueLok™ Hexapod System and Extended Partnership with TSRHC

  Orthofix Announces International Launch of TrueLok™ Hexapod System and
  Extended Partnership with TSRHC

Business Wire

LEWISVILLE, Texas -- November 13, 2012

Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today the
launch of the TrueLok™ Hexapod System, or TL-HEX, through its international
orthopedic distribution network. This external hexapod ring-type fixator for
deformity correction and complex trauma treatment represents the next step in
the evolution of the Company’s TrueLok™ circular fixation platform. The
multi-planar System together with the associated software provides access to
the largest segment of the circular and hybrid fixation markets that are
dominated by one product.

TL-HEX and its software were co-developed with the Company’s partner Texas
Scottish Rite Hospital for Children (TSRHC). This partnership was recently
extended through 2028 and has yielded one of Orthofix’s most successful
orthopedic products.

President and Chief Executive Officer Robert Vaters said, “As a global leader
in external fixation, Orthofix is very excited to initiate its international
launch of TL-HEX, which truly improves the lives of patients who are suffering
from orthopedic deformities or from trauma. With our partners at the Texas
Scottish Rite Hospital for Children, we stay committed to the research and
development of future ground breaking external fixation technology.”

The first surgery was performed by Dr. Franz F Birkholtz in South Africa in

The TrueLok™ Hexapod System is planned to launch during the fourth quarter
2012 in certain international markets and is on display this week at the
annual meetings of the Italian Society of Orthopaedics and Traumatology (SIOT)
in Rome, Italy and the French Society of Orthopedic Surgery and Traumatology
(SOFCOT) in Paris, France.

About Orthofix:

Orthofix International N.V. is a diversified, global medical device company
focused on developing and delivering innovative repair and regenerative
solutions to the spine and orthopedic markets. Orthofix’s products are widely
distributed around the world to orthopedic surgeons and patients via
Orthofix’s sales representatives and its subsidiaries, and via collaborations
with other leading orthopedic product companies. In addition, Orthofix is
collaborating on R&D activities with leading research and clinical
organizations such as the Musculoskeletal Transplant Foundation, the
Orthopedic Research and Education Foundation, and Texas Scottish Rite Hospital
for Children. For more information about Orthofix, please visit

About Texas Scottish Rite Hospital for Children:

Texas Scottish Rite Hospital for Children is one of the nation's leading
pediatric centers for the treatment of orthopedic conditions, certain related
neurological disorders and learning disorders, such as dyslexia. Admission is
open to Texas children from birth up to 18 years of age. Patients receive
treatment regardless of the family's ability to pay. For more information, to
volunteer or to make a donation, please call (214) 559-5000 or (800) 421-1121
or visit www.tsrhc.org.


Orthofix International N.V.
Mark Quick, 214-937-2924
Director of Investor Relations and Business Development
Press spacebar to pause and continue. Press esc to stop.